1[4]Hirasawa H, Sugai T, Oda S, et al. Efficacy and limitation of apheresis therapy in critical care[J]. Therap Ahperesis, 1997, 1:228- 232.
2[6]Yoshiba M, Inovue K, Sekiyama K et al. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure[J]. Artif Organs, 1996,20:1169 - 1172.
3贞广智仁,平泽博之,营井桂雄,他.Critical Care にぉけるCHDF の cytokine除支效果おょびその机序につて[J].日ケフェしシス会志,1999,(18):41-47.
5[10]Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure [J]. Hepatology, 2000, 32:734 - 739.
6[11]Nagaki M, I wai H, Naiki T, et al. High levels of serum interleukin -10 and tumor necrosis factor α are associated with fatality in fulminant hepatitis[J] .J Infect Dis,2000, 182:1103- 1108.
8平野刚,平泽博之,织田成人,他.剧症肝炎(FH)に( )する肝移植の适应と bridge use としての人工肝补助疗法[J].集中治疗,2000,(12):865-872.
9[15]Watanabe FD, Mullon CJ- P, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure [J]. Ann Surg, 1997,225:484 - 494.
10[16]STockmann HBAC, Hiemstra CA, Marquet RL, et al. Extracorporeal perfusion for the treatment of acute liver failure[J].Ann Sure 2000,231:460 - 470.
